Genetic Testing Market Research Report - Forecast till 2027

Genetic Testing Market: Information By Type (Prescribed Genetic Testing and Direct-to-Consumer Genetic Testing), Method (Molecular Genetic Tests/ DNA Tests, Chromosomal Genetic Tests and Biochemical Genetic Tests), By Application (Reproductive Health (Newborn Screening, Prenatal Screening and Carrier Screening), Cancer Screening (Hereditary Cancer, Breast Cancer, Ovarian Cancer and Colon Cancer), Ancestry, Predictive and Pre-Symptomatic Testing and others) - Forecast till 2027

ID: MRFR/HC/1477-CR | February 2021 | Region: Global | 150 Pages         

1 Introduction

1.1 Definition 15

1.2 Scope of the Study 15

1.3 List of Assumptions 16

1.4 Market Structure 16

2 Research Methodology

2.1 Research Process 17

2.2 Primary Research 18

2.3 Secondary Research 19

2.4 Market Size Estimation 20

2.5 Forecast Model 20

3 Market Dynamics

3.1 Introduction 21

3.2 Drivers 22

3.2.1 Rising Awareness About the Benefits of Genetic Testing 22

3.2.2 Rising Prevalence of Genetic Disorders 22

3.2.3 Genetic Tests Play an Important Role in Forensic Investigations 22

3.2.4 Changing Trend in the Industry from Service-Driven to Product-Driven Industry 22

3.3 Restraints 23

3.3.1 Limitations in Genetic Testing and Inaccuracy of Tests 23

3.3.2 High Cost of Tests 23

3.4 Opportunities 23

3.4.1 Growth in Untapped Regions and Developing Economies 23

3.5 Challenges 23

3.5.1 Growth in Exposure to Natural and Man-Made Threats 23

3.6 Macroeconomics 24

3.7 Technology Trends & Assessment 24

4 Market Factor Analysis

4.1 Value Chain Analysis 25

4.1.1 R&D and Designing 25

4.1.2 Manufacturing 25

4.1.3 Distribution & Sales 26

4.1.4 Post-Sales Review 26

4.2 Porter’s Five Forces Model 27

4.2.1 Bargaining Power of Suppliers 28

4.2.2 Bargaining Power of Buyers 28

4.2.3 Threat of New Entrants 28

4.2.4 Threat of Substitutes 28

4.2.5 Intensity of Rivalry 28

4.3 Investment Opportunities Analysis 29

4.4 Pricing Analysis 29

5 Market, by Type

5.1 Introduction 30

5.2 Prescribed Genetic Testing 32

5.3 Direct to Consumer Genetic Testing 33

6 Market, by Method

6.1 Introduction 34

6.2 Molecular Genetic Tests/ DNA Tests 36

6.3 Chromosomal Genetic Tests 37

6.4 Biochemical Genetic Tests 38

7 Market, by Application

7.1 Introduction 39

7.2 Reproductive Health 41

7.2.1 Newborn Screening 42

7.2.2 Prenatal Screening 43

7.2.3 Carrier Screening 43

7.3 Cancer Screening 44

7.3.1 Hereditary Cancer 45

7.3.2 Breast Cancer 46

7.3.3 Ovarian Cancer 46

7.3.4 Colon Cancer 47

7.4 Ancestry 47

7.5 Predictive and Pre-Symptomatic Testing 48

7.6 Others 48

8 Global Market, by Region

8.1 Introduction 49

8.2 Americas 51

Market, by Type

Market, by Method

Market, by Application

8.2.1 North America 54

Market, by Type

Market, by Method

Market, by Application

8.2.1.1 US 58

Market, by Type

Market, by Method

Market, by Application

8.2.1.2 Canada 60

Market, by Type

Market, by Method

Market, by Application

8.2.2 South America 63

Market, by Type

Market, by Method

Market, by Application

8.3 Europe 66

Market, by Type

Market, by Method

Market, by Application

8.3.1 Western Europe 69

Market, by Type

Market, by Method

Market, by Application

8.3.1.1 Germany 73

Market, by Type

Market, by Method

Market, by Application

8.3.1.2 France 75

Market, by Type

Market, by Method

Market, by Application

8.3.1.3 UK 78

Market, by Type

Market, by Method

Market, by Application

8.3.1.4 Italy 80

Market, by Type

Market, by Method

Market, by Application

8.3.1.5 Spain 83

Market, by Type

Market, by Method

Market, by Application

8.3.1.6 Rest of Western Europe 85

Market, by Type

Market, by Method

Market, by Application

8.3.2 Eastern Europe 88

Market, by Type

Market, by Method

Market, by Application

8.4 Asia-Pacific 91

Market, by Type

Market, by Method

Market, by Application

8.4.1 Japan 94

Market, by Type

Market, by Method

Market, by Application

8.4.2 China 97

Market, by Type

Market, by Method

Market, by Application

8.4.3 India 99

Market, by Type

Market, by Method

Market, by Application

8.4.4 Australia 102

Market, by Type

Market, by Method

Market, by Application

8.4.5 South Korea 104

Market, by Type

Market, by Method

Market, by Application

8.4.6 Rest of Asia-Pacific 107

Market, by Type

Market, by Method

Market, by Application

8.5 Middle East and Africa 110

Market, by Type

Market, by Method

Market, by Application

8.5.1 Middle East 113

Market, by Type

Market, by Method

Market, by Application

8.5.2 Africa 116

Market, by Type

Market, by Method

Market, by Application

9 Company Landscape

9.1 Company Share Analysis 119

10 Company Profiles

10.1 Abbott Laboratories 120

10.1.1 Company Overview 120

10.1.2 Financial Overview 120

10.1.3 Products/Services Offered 121

10.1.4 Key Developments 121

10.1.5 SWOT Analysis 121

10.1.6 Key Strategies 122

 

10.2 Bio- Rad Laboratories, Inc. 123

10.2.1 Company Overview 123

10.2.2 Financial Overview 123

10.2.3 Products/Services Offered 124

10.2.4 Key Developments 124

10.2.5 SWOT Analysis 124

10.2.6 Key Strategies 125

10.3 Illumina Inc. 126

10.3.1 Company Overview 126

10.3.2 Financial Overview 126

10.3.3 Products/Services Offered 127

10.3.4 Key Developments 127

10.3.5 SWOT Analysis 128

10.3.6 Key Strategies 128

10.4 Myriad Genetics, Inc. 129

10.4.1 Company Overview 129

10.4.2 Financial Overview 129

10.4.3 Products/Services Offered 130

10.4.4 Key Developments 130

10.4.5 SWOT Analysis 131

10.4.6 Key Strategies 131

10.5 PerkinElmer Inc. 132

10.5.1 Company Overview 132

10.5.2 Financial Overview 132

10.5.3 Products/Services Offered 133

10.5.4 Key Developments 133

10.5.5 SWOT Analysis 133

10.5.6 Key Strategies 133

10.6 QIAGEN 134

10.6.1 Company Overview 134

10.6.2 Financial Overview 134

10.6.3 Products/Services Offered 135

10.6.4 Key Developments 135

10.6.5 SWOT Analysis 135

10.6.6 Key Strategies 136

10.7 Quest Diagnostics Incorporated 137

10.7.1 Company Overview 137

10.7.2 Financial Overview 137

10.7.3 Products/Services Offered 138

10.7.4 Key Developments 138

10.7.5 SWOT Analysis 138

10.7.6 Key Strategies 138

10.8 Eurofins Scientific 139

10.8.1 Company Overview 139

10.8.2 Financial Overview 139

10.8.3 Products/Services Offered 140

10.8.4 Key Developments 140

10.8.5 SWOT Analysis 140

10.8.6 Key Strategies 141

10.9 F. Hoffmann-La Roche Ltd 142

10.9.1 Company Overview 142

10.9.2 Financial Overview 142

10.9.3 Products/Services Offered 143

10.9.4 Key Developments 143

10.9.5 SWOT Analysis 143

10.9.6 Key Strategies 143

10.10 Blueprint Genetics 144

10.10.1 Company Overview 144

10.10.2 Financial Overview 144

10.10.3 Products/Services Offered 144

10.10.4 Key Developments 144

10.10.5 SWOT Analysis 144

10.10.6 Key Strategies 145

10.11 Thermo Fisher Scientific Inc. 146

10.11.1 Company Overview 146

10.11.2 Financial Overview 146

10.11.3 Products/Services Offered 147

10.11.4 Key Developments 147

10.11.5 SWOT Analysis 147

10.11.6 Key Strategies 148

10.12 BGI Genomics 149

10.12.1 Company Overview 149

10.12.2 Financial Overview 149

10.12.3 Products/Services Offered 149

10.12.4 Key Developments 149

10.12.5 SWOT Analysis 150

10.12.6 Key Strategies 150

11 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 16

TABLE 2 GLOBAL GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 31

TABLE 3 GLOBAL GENETIC TESTING MARKET FOR PRESCRIBED GENETIC TESTING, BY REGION, 2020–2027 (USD MILLION) 32

TABLE 4 GLOBAL GENETIC TESTING MARKET FOR DIRECT TO CONSUMER GENETIC TESTING, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 5 GLOBAL GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 35

TABLE 6 GLOBAL GENETIC TESTING MARKET FOR MOLECULAR GENETIC TESTS/ DNA TESTS, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 7 GLOBAL GENETIC TESTING MARKET FOR CHROMOSOMAL GENETIC TESTS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 8 GLOBAL GENETIC TESTING MARKET FOR BIOCHEMICAL GENETIC TESTS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 40

TABLE 10 GLOBAL GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 41

TABLE 11 GLOBAL GENETIC TESTING MARKET FOR REPRODUCTIVE HEALTH, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 12 GLOBAL GENETIC TESTING MARKET FOR NEWBORN SCREENING, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 13 GLOBAL GENETIC TESTING MARKET FOR PRENATAL SCREENING, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 14 GLOBAL GENETIC TESTING MARKET FOR CARRIER SCREENING, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 15 GLOBAL GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 44

TABLE 16 GLOBAL GENETIC TESTING MARKET FOR CANCER SCREENING, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 17 GLOBAL GENETIC TESTING MARKET FOR HEREDITARY CANCER, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 18 GLOBAL GENETIC TESTING MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 19 GLOBAL GENETIC TESTING MARKET FOR OVARIAN CANCER, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 20 GLOBAL GENETIC TESTING MARKET FOR COLON CANCER, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 21 GLOBAL GENETIC TESTING MARKET FOR ANCESTRY, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 22 GLOBAL GENETIC TESTING MARKET FOR PREDICTIVE AND PRE-SYMPTOMATIC TESTING, BY REGION,

2020–2027 (USD MILLION) 48

TABLE 23 GLOBAL GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 50

TABLE 24 AMERICAS: GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 25 AMERICAS: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 26 AMERICAS: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 52

TABLE 27 AMERICAS: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 53

TABLE 28 AMERICAS: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 29 AMERICAS: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 30 NORTH AMERICA: GENETIC TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

TABLE 31 NORTH AMERICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 32 NORTH AMERICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 56

TABLE 33 NORTH AMERICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 56

TABLE 34 NORTH AMERICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 35 NORTH AMERICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 36 US: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 37 US: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 58

TABLE 38 US: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 59

TABLE 39 US: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 40 US: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 41 CANADA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 42 CANADA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 61

TABLE 43 CANADA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 61

TABLE 44 CANADA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 45 CANADA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 46 SOUTH AMERICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 47 SOUTH AMERICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 63

TABLE 48 SOUTH AMERICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 64

TABLE 49 SOUTH AMERICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 50 SOUTH AMERICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 51 EUROPE: GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 52 EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 53 EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 67

TABLE 54 EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 68

TABLE 55 EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 56 EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 57 WESTERN EUROPE: GENETIC TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 70

TABLE 58 WESTERN EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 59 WESTERN EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 71

TABLE 60 WESTERN EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 71

TABLE 61 WESTERN EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 62 WESTERN EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 63 GERMANY: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 64 GERMANY: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 73

TABLE 65 GERMANY: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 74

TABLE 66 GERMANY: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 67 GERMANY: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 68 FRANCE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 69 FRANCE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 76

TABLE 70 FRANCE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 76

TABLE 71 FRANCE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 72 FRANCE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 73 UK: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 74 UK: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 78

TABLE 75 UK: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 79

TABLE 76 UK: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 77 UK: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 78 ITALY: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 79 ITALY: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 81

TABLE 80 ITALY: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81

TABLE 81 ITALY: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 82 ITALY: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 83 SPAIN: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 84 SPAIN: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 83

TABLE 85 SPAIN: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84

TABLE 86 SPAIN: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 87 SPAIN: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 88 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 89 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 86

TABLE 90 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86

TABLE 91 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 92 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 93 EASTERN EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 94 EASTERN EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 88

TABLE 95 EASTERN EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89

TABLE 96 EASTERN EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 97 EASTERN EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 98 ASIA-PACIFIC: GENETIC TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91

TABLE 99 ASIA-PACIFIC: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 100 ASIA-PACIFIC: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 92

TABLE 101 ASIA-PACIFIC: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93

TABLE 102 ASIA-PACIFIC: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 103 ASIA-PACIFIC: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 104 JAPAN: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 105 JAPAN: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 95

TABLE 106 JAPAN: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95

TABLE 107 JAPAN: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 108 JAPAN: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 109 CHINA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 110 CHINA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 97

TABLE 111 CHINA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98

TABLE 112 CHINA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 113 CHINA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 114 INDIA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 115 INDIA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100

TABLE 116 INDIA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100

TABLE 117 INDIA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 118 INDIA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 119 AUSTRALIA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 120 AUSTRALIA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 102

TABLE 121 AUSTRALIA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103

TABLE 122 AUSTRALIA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 123 AUSTRALIA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 124 SOUTH KOREA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 125 SOUTH KOREA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 105

TABLE 126 SOUTH KOREA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105

TABLE 127 SOUTH KOREA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 128 SOUTH KOREA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 129 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 130 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 107

TABLE 131 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 108

TABLE 132 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 133 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 109

TABLE 134 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 110

TABLE 135 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 136 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 111

TABLE 137 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112

TABLE 138 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 139 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 140 MIDDLE EAST: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 141 MIDDLE EAST: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 114

TABLE 142 MIDDLE EAST: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114

TABLE 143 MIDDLE EAST: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 144 MIDDLE EAST: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 145 AFRICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 116

TABLE 146 AFRICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 116

TABLE 147 AFRICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117

TABLE 148 AFRICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 149 AFRICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 118

12 List of Figures

FIGURE 1 GLOBAL GENETIC TESTING MARKET: MARKET STRUCTURE 16

FIGURE 2 RESEARCH PROCESS OF MRFR 17

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 20

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MARKET 21

FIGURE 5 VALUE CHAIN: GLOBAL MARKET 25

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL MARKET 27

FIGURE 7 GLOBAL MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 30

FIGURE 8 GLOBAL MARKET, BY METHOD, 2020 & 2027 (USD MILLION) 34

FIGURE 9 GLOBAL MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 39

FIGURE 10 GLOBAL MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020 & 2027 (USD MILLION) 41

FIGURE 11 GLOBAL MARKET, FOR CANCER SCREENING, BY TYPE, 2020 & 2027 (USD MILLION) 44

FIGURE 12 GLOBAL, MARKET BY REGION, 2020 & 2027 (USD MILLION) 49

FIGURE 13 AMERICAS: MARKET SHARE, BY REGION, 2020 (%) 51

FIGURE 14 NORTH AMERICA: GENETIC TESTING MARKET SHARE, BY COUNTRY, 2020 (%) 54

FIGURE 15 EUROPE: MARKET SHARE, BY REGION, 2020 (%) 66

FIGURE 16 WESTERN EUROPE: MARKET SHARE, BY COUNTRY, 2020 (%) 69

FIGURE 17 ASIA-PACIFIC: MARKET SHARE, BY COUNTRY, 2020 (%) 91

FIGURE 18 MIDDLE EAST & AFRICA: MARKET SHARE, BY REGION, 2020 (%) 110

FIGURE 19 GLOBAL MARKET, COMPANY SHARE ANALYSIS, 2020 (%) 119

Genetic Testing Market

Genetic Testing Market is projected to register at a CAGR of 10.30% and is expected to acquire a market value of USD 30.10 Billion by 2027

Segmentation

By Type Prescribed Genetic Testing Direct To Consumer Genetic Testing
By Method Molecular Genetic Tests/ Dna Tests Chromosomal Genetic Tests Biochemical Genetic Tests
By Application Reproductive Health Cancer Screening Ancestry Predictive And Pre Symptomatic Testing Others

Key Players

  • PerkinElmer Inc. (US)
  • Myriad Genetics Inc. (US)
  • Abbott Laboratories (US)
  • Illumina Inc. (US)
  • Bio-Rad Laboratories Inc. (the US)
  • QIAGEN (Germany)
  • Eurofins Scientific (US)
  • Quest Diagnostics Incorporated (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific Inc. (US)

Drivers

  • Increasing prevalence of genetic disorders
  • Increasing need to find a cure to cancer
Speak to Analyst Request a Free Sample

Genetic Testing Market Overview


According to the analysis conducted by Market Research Future (MRFR), the Genetic Testing Market is projected to thrive at a CAGR of 10.30% and is expected to acquire a market value of USD 30.10 Billion by 2027.


Genetic testing is used in prenatal screening, diagnostics, and as a predictive tool. The genetic testing market is predicted to propel due to the on-going development in the field to produce useful testing kits. Overall, the genetic testing market is likely to experience significant expansion due to its growing requirement, rising acquisitions, and partnerships among key players.


The outbreak of COVID-19 has severely impacted the genetic testing market. The worldwide lockdown to follow social distancing resulted in various challenges in the genetic testing market. COVID-19 resulted in the shutdown of testing labs and clinics, which has restricted face-to-face genetic counseling that is likely to impact the market negatively.


Market Dynamics


The growing demand for genetic testing in oncology and the rising adoption of genetic tests into clinical care is predicted to propel the genetic testing market during the projection tenure. The surging need for personalized medicine is another salient cause that can augment the genetic testing market size.


However, concerns regarding the standardization of genetic testing-based diagnostics and strict rules implemented for product approvals are expected to obstruct the genetic testing market growth during the assessment period.


Drivers


Rising Prevalence of Genetic Disorders


The rising awareness about the benefits of genetic testing and the increasing prevalence of genetic disorders are primary drivers for the growth of the genetic testing market. The increasing need to find a cure to cancer is expected to create a demand for effective testing that can augment the global cancer testing market. Additionally, the rapid expansion of the biotechnology sector are expected to propel the genetic testing market significantly in the assessment period.


Opportunities


Integration of AI in Testing Procedures


The integration of AI and other smart technologies in genetic testing is expected to offer various market expansion opportunities during the forecast period. Besides, the innovation in product design and strong distribution partnerships are other factors that can provide lucrative chances to grow the trade.


Restraints


Lack of Expertise to Hinder the Market Growth


Despite the presence of various lucrative opportunities that can grow the market, the shortage of trained technicians is a significant factor that can hinder the genetic testing market in emerging economies.


Challenges


Lack of Medical Solutions for all the Diseases Diagnosed


The biggest challenge for the genetic testing market is the lack of solutions for all the diseases diagnosed. However, funded research in prognosis post the detection can counter the challenge mentioned above.


Cumulative Growth Analysis


The genetic testing market is expected to expand rapidly during the forecast period due to the rising awareness of genetic disorders. The industry is anticipated to witness various opportunities for expansion in the coming period.


Market Segmentation


By Type


Prescribed Genetic Testing Segment to Hold Maximum Market Share


Based on type, the global genetic testing market has been segmented into direct to consumer genetic testing and prescribed genetic testing. Among all genetic testing market segments, the prescribed genetic testing market is anticipated to expand at the highest CAGR while acquiring the USD 21653.91 million market value by 2024.


By Method


Molecular Genetic Test/DNA Tests to Hold the Maximum Market Share


Based on the method, the global genetic testing market has been segmented into chromosomal genetic tests, molecular genetic tests/ DNA tests, and biochemical, genetic tests. Among all, the molecular genetic/DNA tests is expected to lead the global market while thriving at a CAGR of 11.78% during the forecast period.


By Application


Reproductive Health Segment to Acquire the Largest Market Share


Based on application, the global market has been segmented into cancer screening, reproductive health, ancestry, predictive and pre-symptomatic testing, and others. Among all, the reproductive health segment is expected to dominate the market.


Regional Analysis


The Americas to Dominate the Market Owing to the Increasing Incidences of Genetic Disorders


The Americas is expected to dominate the market for genetic testing due to the growing incidences of a genetic disorder and increasing demand for personalized genetic testing. The growing government support and the presence of the advanced healthcare sector is expected to boost the regional market during the forecast period.


APAC is expected to be the fastest-growing market due to the expanding patient pool and untapped market opportunities in the evolving countries. Besides, the growing initiatives to develop healthcare infrastructure to meet the demand for the rising geriatric population can further propel the regional market during the review tenure.


The European market for genetic testing is projected to be the second-largest during the forecast period. Recent developments and advances in molecular medicines in Europe are critical factors for the growth of this genetic testing market. The increasing prevalence of genetic diseases and disorders has expanded the scope for the development of different genetic tests.


MEA is expected to grow due to the aging population, a rise in the number of chronic diseases such as cancer, and innovations in genetic testing.


Competitive Landscape


Product Innovation in Genetic Testing Platforms to Grow Competition among the Key Players


The market for genetic testing is highly competitive and comprises several established players. The on-going innovation and technical development in genetic testing platforms by various renowned players are likely to enhance the competitiveness of the market.


Industry News


November 2020: Taysha Gene Therapies, a US-based company, and Invitae, another US-based health startup, have announced a partnership to support Invitae’s Detect Lysosomal Storage Diseases ( Detect LSDs) and Behind the Seizure programs by offering free genetic testing to patients.


Behind the Seizure is a cross-company collaboration among the companies of the US and Canada, which is designed to increase access to genetic testing for children who experience seizures during their childhood.


Key Players



  • PerkinElmer Inc. (US)

  • Myriad Genetics Inc. (US)

  • Abbott Laboratories (US)

  • Illumina Inc. (US)

  • Bio-Rad Laboratories Inc. (the US)

  • QIAGEN (Germany)

  • Eurofins Scientific (US)

  • Quest Diagnostics Incorporated (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Thermo Fisher Scientific Inc. (US)

  • Blueprint Genetics (Finland)

  • BGI Genomics (China)


Recent Developments


December 2020: A Singapore-based Medtech company, known as Cell ID Pte. Ltd., has developed a palm-sized portable genetic test that uses an app on a laptop to detect if the person has COVID-19. The test uses biotechnology to perform two-tests at a time outside of the laboratory.


November 2020: Agios Pharmaceuticals, a public American pharmaceutical company, announced that it had partnered with PerkinElmer Genomics, a US-based renowned molecular genetics laboratory, on a genetic testing program for patients with anticipated hereditary anemias.


December 2020: Illumina, Inc, a renowned America genetic testing company, and Harvard Pilgrim Health Care, another US-based key player, announced a risk-sharing agreement to make whole-genome sequencing (WGS) available to few Harvard Pilgrim members. The program will leverage WGS to support a faster diagnosis of genetic diseases in children.


November 2020: Sanofi, a renowned French multinational pharmaceutical company, announced that it would sponsor Parkinson’s Foundation’s genetic study with 1 million for free testing.


Report Overview


The global genetic testing market is anticipated to witness significant growth during the forecast period owing to the rising demand for genetic testing and the rising prevalence of genetic disorders.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 30.10 Billion
  CAGR   10.30% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Method, Application, Cancer Screening,
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   PerkinElmer Inc. (US), Myriad Genetics Inc. (US), Abbott Laboratories (US), Illumina Inc. (US), Bio-Rad Laboratories Inc. (the US), QIAGEN (Germany), Eurofins Scientific (US), Quest Diagnostics Incorporated (US), Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Blueprint Genetics (Finland), BGI Genomics (China)
  Key Market Opportunities   Integration of AI in Testing Procedures
  Key Market Drivers   Rising Prevalence of Genetic Disorders


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Genetic testing market volume by 2027 would be USD 30.10 Billion

The genetic testing market would attain a CAGR of 10.30% By 2027

High cost and inaccuracy could prevent the genetic testing market growth.

The Americas would have a maximum genetic testing market share.

Japan had a 27.7% share of the Asia Pacific genetic testing market in 2018.